Article Figures & Data
Figures
- Figure 1.
Disposition of trial participants.
- Figure 2.
Mean ± SD estimated GFR from baseline to 20-month follow-up by trial group.
Tables
Median (IQR) P Values for the Difference Experimental Intervention (n = 238) Standard Care Control (n = 236) Age (years) 67 (62, 72) 67 (61, 72) 0.85 Baseline serum creatinine (μmol/L) 127 (112, 145) 128 (114, 143) 0.85 Baseline eGFR (ml/min per 1.73 m2) 42 (40, 46) 42 (37, 46) 0.78 Weight (kg) 83 (72, 96) 82 (72, 91) 0.33 Systolic BP 128 (116, 140) 132 (120, 144) 0.001 Diastolic BP 74 (66, 80) 74 (68, 81) 0.96 Proteinuria (g/day) 0.11 (0.07, 0.2) 0.12 (0.08, 0.22) 0.06 LDL cholesterol (mmol/L) 2.6 (2.1, 3.3) 2.7 (2.1, 3.5) 0.07 Hba1c among diabetics (%) 6.9 (6.4, 7.9) 7.1 (6.3, 7.6) 0.58 Hemoglobin (g/L) 136 (125, 144) 134 (126, 144) 0.33 Number (%) Number (%) Female 131 (55) 132 (56) 0.85 Caucasian 223 (94) 224 (95) 0.28 Retired 144 (61) 158 (67) 0.15 Working 58 (24) 55 (23) 0.42 Post-secondary school education 96 (40) 100 (42) 0.90 Married/living as married 167 (70) 154 (65) 0.37 Living in own home, no hired assistance 224 (94) 219 (93) 0.77 Current smoker 18 (8) 18 (8) 1.0 Systolic BP >130 mmHg 84 (36) 120 (51) 0.001 Systolic BP >140 mmHg 61 (26) 81 (35) 0.05 Diastolic BP >80 mmHg 40 (17) 60 (26) 0.03 Diastolic BP >90 mmHg 10 (4) 11 (5) 0.98 Diabetes mellitus 73 (31) 76 (33) 0.65 Angina 19 (8) 28 (12) 0.21 History of myocardial infarction 39 (17) 33 (14) 0.55 History of PTCA 26 (11) 20 (9) 0.46 History of CABG 25 (11) 19 (8) 0.45 History of heart failure 13 (6) 9 (4) 0.53 History of cardiac arrhythmia 32 (14) 32 (14) 1.0 History of cerebrovascular event 10 (4) 15 (7) 0.40 History of hypertension 182 (78) 178 (77) 0.87 History of chronic lung disease 46 (20) 49 (21) 0.78 History of cancer 34 (15) 40 (17) 0.50 Taking an ACE inhibitor or ARB 165 (70) 156 (66) 0.51 Taking a statin 118 (25) 103 (22) 0.23 PTCA, percutaneous transluminal coronary angioplast; CABG, coronary artery bypass graft; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker. Continuous variables are presented as medians (intraquartile range). Binary variables are presented as numbers (percentages).
Time Experimental Intervention Number (%) Standard Care Control Number (%) P BP ≤130/80 Baseline 139/236 (59) 101/235 (43) 0.03a 12 months 134/218 (61.5) 100/218 (45.9) 0.47b 24 months 81/128 (63.2) 64/136 (47) 0.76c LDL <2.5 mmol/L Baseline 99/230 (43) 81/220 (36.8) 0.41a 12 months 97/206 (47.1) 99/214 (46.3) <0.001b 24 months 78/122 (63.9) 76/128 (59.4) 0.74c On RAAS blocker Baseline 165/236 (70) 156/235 (66) 0.49a 12 months 165/219 (75) 146/220 (66) 0.92b 24 months 102/130 (78) 92/140 (66) 0.06c Hba1c ≤7.0% in diabetics Baseline 38/68 (55.9) 36/74 (48.6) 0.58a 12 months 50/70 (71.4) 52/77 (67.5) <0.001b 24 months 40/49 (81.6) 43/52 (82.7) 0.76c Hemoglobin ≥105 g/L Baseline 229/235 (97.4) 232/234 (99.1) 0.81a 12 months 208/214 (97.2) 203/214 (94.8) 0.07b 24 months 125/128 (97.7) 130/136 (95.6) 0.64c Iron saturation ≥0.2 Baseline 169/225 (75.1) 160/226 (70.8) 0.28a 12 months 154/210 (73.3) 155/210 (73.8) 0.24b 24 months 95/128 (74.2) 95/124 (76.6) 0.31c Serum phosphate <1.8 mmol/L Baseline 235/235 (100) 233/233 (100) NA 12 months 211/211 (100) 218/218 (100) NA 24 months 125/126 (99.2) 126/127 (99.2) NA Bicarbonate ≥22 mmol/L Baseline 225/234 (96.1) 230/234 (98.3) 0.18a 12 months 209/215 (97.2) 212/214 (99.1) 0.68b 24 months 124/127 (97.6) 124/127 (97.6) 0.37c All of the P values are from generalized estimating equations. NA, statistical analysis is not applicable as target was almost uniformly met. RAAS, renin-angiotensin-aldosterone.
↵a Comparison at baseline.
↵b Comparison over time within group.
↵c Comparison between groups over time adjusted for baseline.
Experimental Intervention (n = 238) Standard Care Control (n = 236) Cardiovascular death 2 (0.8) 2 (0.8) Other death 5 (2.1) 0 (0.0) Myocardial infarction 5 (2.1) 4 (1.7) Acute coronary syndrome 1 (0.4) 2 (0.8) Congestive heart failure 5 (2.1) 8 (3.4) Stroke 1 (0.4) 1 (0.4) Amputation above ankle 2 (0.8) 2 (0.8) Dialysis 2 (0.8) 1 (0.4) Doubled serum creatinine 1 (0.4) 4 (1.7) Total cases with ≥1 event 19 (8.0) 19 (8.0) Total events 24 24 Event rate per year (%) 5.3 5.2 The proportions are presented as numbers (percentages).
In this issue
A Nurse-coordinated Model of Care versus Usual Care for Stage 3/4 Chronic Kidney Disease in the Community: A Randomized Controlled Trial
Jump to section
More in this TOC Section
Original Articles
Cited By...
- Nephrology consultation and mortality in people with stage 4 chronic kidney disease: a population-based study
- Person-Centered Integrated Care for Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Effectiveness of Quality Improvement Strategies for the Management of CKD: A Meta-Analysis
- Nurse Practitioner Care Improves Renal Outcome in Patients with CKD
- Effect of shared care on blood pressure in patients with chronic kidney disease: a cluster randomised controlled trial
- Nephrology Care in a Fully Integrated Care Model: Lessons from the Geisinger Health System